(Q30868628)

27 June 2017

1 reference

title

Neuroimaging in Parkinson disease: from research setting to clinical practice (English)

1 reference

27 June 2017

1 reference

0 references

Marios Politis

1

1 reference

27 June 2017

language of work or name

English

0 references

publication date

11 November 2014

1 reference

27 June 2017

published in

Nature Reviews Neurology

1 reference

27 June 2017

volume

10

1 reference

27 June 2017

issue

12

1 reference

27 June 2017

page(s)

708-722

1 reference

The economic cost of brain disorders in Europe

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The aging brain and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Parkinson's disease symptoms: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3‐month observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The relationship between cerebral vascular disease and parkinsonism: The VADO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

FDG PET in the differential diagnosis of parkinsonian disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Validation of parkinsonian disease-related metabolic brain patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Degenerative changes were common in brain magnetic resonance imaging in patients with newly diagnosed Parkinson's disease in a population-based cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Automated, high accuracy classification of Parkinsonian disorders: a pattern recognition approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Changes in network activity with the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Resting state functional connectivity of the striatum in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differences in brain activation between tremor- and nontremor-dominant Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Isolated tremor and disruption of the nigrostriatal dopaminergic system: An 18F-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

History of falls in Parkinson disease is associated with reduced cholinergic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The pedunculopontine nucleus: its role in the genesis of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Regional gray matter atrophy in patients with Parkinson disease and freezing of gait.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Pattern of brain tissue loss associated with freezing of gait in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Exploring the cortical and subcortical functional magnetic resonance imaging changes associated with freezing in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Striatal dopa and glucose metabolism in PD patients with freezing of gait.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dyskinesias in Parkinson's disease: views from positron emission tomography studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Forced collectionism after orbitofrontal damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Measuring fatigue in patients with Parkinson's disease - the Fatigue Severity Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Weight change and body composition in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonergic mediated body mass index changes in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonin 2A receptors and visual hallucinations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Visual hallucination in Parkinson's disease with FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Impulse control disorders in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Compulsive drug use linked to sensitized ventral striatal dopamine transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

A systematic review of prevalence studies of dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

[11C]PIB binding in Parkinson's disease dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

In vivo imaging of the integration and function of nigral grafts in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dyskinesia after fetal cell transplantation for parkinsonism: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Clinical application of stem cell therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

PET/MRI for neurologic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Simultaneous MR/PET imaging of the human brain: feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

MR-Based PET attenuation correction for PET/MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

MRI for attenuation correction in PET: methods and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Progression of cortical thinning in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Serotonin in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dopamine receptor mapping with PET imaging in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Differential diagnosis tool for parkinsonian syndrome using multiple structural brain measures.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Age-specific progression of nigrostriatal dysfunction in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Transplantation of fetal mesencephalic tissue in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Dyskinesias following neural transplantation in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.205

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

31 March 2020

1 reference

12 December 2020

SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease

1 reference

12 December 2020

Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy

1 reference

12 December 2020

Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity.

1 reference

12 December 2020

Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.

1 reference

12 December 2020

Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample

1 reference

12 December 2020

10.1038/NRNEUROL.2014.205

Identifiers

DOI

1 reference

Dimensions Publication ID

27 June 2017

1009908711

0 references

1 reference